Public Views of Gene Editing for Babies Depend on How It Would Be Used
By Cary Funk and Meg Hefferon,
Pew Research Center
| 07. 26. 2018
Americans’ views on the appropriateness of changing a baby’s genetic characteristics depend in large part on the intended purpose and on whether or not human embryos would be used in testing these techniques. A majority of Americans support the idea of using gene editing with the goal of delivering direct health benefits for babies, but at the same time, a majority considers the use of such techniques to boost a baby’s intelligence something that takes technology “too far.”
About seven-in-ten Americans (72%) say that changing an unborn baby’s genetic characteristics to treat a serious disease or condition that the baby would have at birth is an appropriate use of medical technology, while 27% say this would be taking technology too far. A somewhat smaller share of Americans say gene editing to reduce a baby’s risk of developing a serious disease or condition over their lifetime is appropriate (60% say this, while 38% say it would be taking medical technology too far). But just 19% of Americans say it would be appropriate to use gene editing to make a baby more...
Related Articles
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Émile P. Torres, Truthdig | 02.26.2026
It’s well known that Jeffrey Epstein was a super-wealthy pedophile with an extraordinary network of powerful friends: tech billionaires, politicians and academics. But few people know that he was also a transhumanist — someone who believes that we should...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...